Patent application number | Description | Published |
20080197316 | MINERAL FIBER INSULATION HAVING THERMOPLASTIC POLYMER BINDER AND METHOD OF MAKING THE SAME - A method of forming a fibrous insulation product includes forming at least one fibrous veil including first fibers and blowing a non-aqueous, formaldehyde-free, thermoplastic binder in powder, liquid or fibrous form into said veil during said forming step to form a mixture of the binder and the first fibers. When in fibrous form, the binder fibers have average length of less than or equal to about 15 mm. The mixture is collected on the forming belt and formed into an insulation batt, board or molding media. | 08-21-2008 |
20090053958 | INSULATION PRODUCT FROM ROTARY AND TEXTILE INORGANIC FIBERS WITH IMPROVED BINDER COMPONENT AND METHOD OF MAKING SAME - An insulation product includes a fibrous web of first fibers, rotary glass fibers, and textile glass fibers. A binder is blended with the fibrous web. The binder bonds the fibers together to form the insulation product. The binder includes a thermoplastic binder component and a powdered binder component. | 02-26-2009 |
20090140464 | METHOD FOR CURING A BINDER ON INSULATION FIBERS - The invention relates to curing a binder on fibrous insulation wherein, heated gas flows as a ratio of, an upward flow into the fibrous insulation, and a downward flow into the fibrous insulation, to heat the binder to its curing temperature; and the binder is cooled, thereby curing at least a portion of the binder to a thermoset state. When a remainder of the binder remains uncured, another stage of heating the binder with a ratio of heated gas followed by cooling, will cure the remainder of the binder. | 06-04-2009 |
Patent application number | Description | Published |
20100284982 | Erythrocyte-encapsulated L-asparaginase for enhanced acute lymphoblastic leukemia therapy - Compositions for transporting L-asparaginase across the cellular membrane of erythrocytes, comprising a low molecular weight protamine peptide. Process of preparation of compositions comprising conjugates of L-asparaginase and a low molecular weight protamine peptide. Method of treatment comprising administration of adapted L-asparaginase is also described. | 11-11-2010 |
20110114870 | SUPERINSULATION WITH NANOPORES - This invention relates to the field of thermal insulation. In particular, the invention describes superinsulation articles having a desired porosity, reduced pore size and cost-effective methods for manufacturing such articles. In one aspect of the present invention, the article may comprise a material system with at least about 20% porosity. In a further aspect of the invention, an article may comprise greater than about 25% of nanopores having a pore size no greater than about 1500 nanometers in its shortest axis. | 05-19-2011 |
20140329922 | Superinsulation with Nanopores - This invention relates to the field of thermal insulation. In particular, the invention describes superinsulation articles having a desired porosity, reduced pore size and cost-effective methods for manufacturing such articles. In one aspect of the present invention, the article may comprise a material system with at least about 20% porosity. In a further aspect of the invention, an article may comprise greater than about 25% of nanopores having a pore size no greater than about 1500 nanometers in its shortest axis. | 11-06-2014 |
Patent application number | Description | Published |
20100316268 | SYSTEM, METHOD, APPARATUS, AND COMPUTER PROGRAM FOR INTERACTIVE PRE-OPERATIVE ASSESSMENT - A procedure for pre-operating assessment of one or more anatomical structures generated from medical images and provided in a rendered 3D space, and an imaging system, apparatus, and computer program, that operate in accordance with the procedure. The procedure comprises providing one or more safety margin indicators in the rendered 3D space, each having a shape corresponding to that of a respective one of the anatomical structures within an organ and having a predetermined size of safety margin from the respective one of the anatomical structures. The procedure also comprises manipulating at least one of the shape and predetermined size of safety margin of at least one of the safety margin indicators in the rendered 3D space, and immediately providing a rendering in the 3D space of a manipulated version of the at least one safety margin indicator. Also provided is a procedure for defining at least one cutting surface to resect one or more medical anatomical structures using an imaging system. | 12-16-2010 |
20100316277 | Method, system, apparatus, and computer program product for interactive hepatic vascular and biliary system assessment - A procedure for image segmentation on three-dimensional (3D) medical images, and a system, apparatus, and computer program that operate in accordance with the procedure. The procedure includes generating a projection including an anatomic structure, tracing a curve corresponding to the anatomic structure, extracting a curved volume of interest based on the curve and the projection, and extracting a segmentation of the anatomic structure. Also provided is a procedure for aligning anatomic structures in images, and a system, apparatus, and computer program that operate in accordance with the procedure. The procedure includes determining part of a biliary system in a first image, determining part of a hepatic portal vein or a hepatic artery in a second image, determining a gallbladder in the images, determining a cost function, and aligning the biliary system and the hepatic portal vein or hepatic artery by maximizing the cost function. | 12-16-2010 |
20120209106 | SYSTEM AND METHOD FOR INTERACTIVE THREE DIMENSIONAL OPERATION GUIDANCE SYSTEM FOR SOFT ORGANS BASED ON ANATOMIC MAP - A system for providing visual three dimensional assistance to a user during a medical procedure involving a soft organ. The system and method provide visual assistance to a user during a medical procedure involving a soft organ. The system and method utilize a processor for generating an image of the soft organ, a surgical instrument tracker for tracking a surgical instrument during the medical procedure, and a display in communication with the processor and the surgical instrument tracker for visually displaying in three dimensions, the image of the soft organ and the surgical instrument in relation to the soft organ. | 08-16-2012 |
Patent application number | Description | Published |
20090230361 | MODIFIED PLANARIZNG AGENTS AND DEVICES - A composition comprising: at least one conjugated polymer, at least one second polymer comprising repeat units represented by: (I) optionally, —[CH | 09-17-2009 |
20090256117 | DOPED CONJUGATED POLYMERS, DEVICES, AND METHODS OF MAKING DEVICES - Use of certain materials in hole injection or hole transport layers can improve the operational lifetimes in organic electronic devices. Compositions comprising a doped conjugated polymer, doped with a redox dopant, including iodonium salt, can increase lifetimes. Inks can be formulated and cast as films in organic electronic devices including OLEDs, PHOLEDs, and OPVs. One embodiment provides a composition with a conjugated polymer doped with a redox dopant. Non-aqueous based inks can be formulated. Iodonium salts can be used. | 10-15-2009 |
20140323637 | MODIFIED PLANARIZNG AGENTS AND DEVICES - A composition comprising: at least one conjugated polymer, at least one second polymer comprising repeat units represented by: (I) optionally, —[CH | 10-30-2014 |
20150028322 | DOPED CONJUGATED POLYMERS, DEVICES, AND METHODS OF MAKING DEVICES - Use of certain materials in hole injection or hole transport layers can improve the operational lifetimes in organic electronic devices. Compositions comprising a doped conjugated polymer, doped with a redox dopant, including iodonium salt, can increase lifetimes. Inks can be formulated and cast as films in organic electronic devices including OLEDs, PHOLEDs, and OPVs. One embodiment provides a composition with a conjugated polymer doped with a redox dopant. Non-aqueous based inks can be formulated. Iodonium salts can be used. | 01-29-2015 |
Patent application number | Description | Published |
20090124668 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY - The present application describes modulators of MCP-1 of formula (I): | 05-14-2009 |
20100113489 | MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY, CRYSTALLINE FORMS AND PROCESS - The present invention provides a novel antagonist or partial agonists/antagonist of MCP-1 receptor activity: N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin- 4-ylamino)pyrrolidin-1-yl)cyclohexyl)acetamide, or a pharmaceutically acceptable salt, solvate or prodrug, thereof, having an unexpected combination of desirable pharmacological characteristics. Crystalline forms of the present invention are also provided. Pharmaceutical compositions containing the same and methods of using the same as agents for the treatment of inflammatory diseases, allergic, autoimmune, metabolic, cancer and/or cardiovascular diseases is also an objective of this invention. The present disclosure also provides a process for preparing compounds of Formula (I), including N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino)pyrrolidin-1-yl)cyclohexyl)acetamide: | 05-06-2010 |
20110059940 | 2-Aryl Glycinamide Derivatives - The disclosure provides compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their uses in inhibiting β-amyloid peptide (β-AP) production. | 03-10-2011 |
20160052888 | SUBSTITUTED BICYCLIC COMPOUNDS - Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): | 02-25-2016 |
Patent application number | Description | Published |
20120058174 | FABRICATION OF INTERCONNECTED MODEL VASCULATURE - Methods of fabricating a substantially interconnected model vasculature, as well as compositions formed from such methods are provided. In some embodiments, the methods may comprise forming a non-woven fiber network comprising a plurality of fibers and a void space; backfilling the void space of the fiber network; and removing the fibers to form a substantially interconnected vascular network. | 03-08-2012 |
20140220555 | IN VITRO MICROPHYSIOLOGICAL SYSTEM FOR HIGH THROUGHPUT 3D TISSUE ORGANIZATION AND BIOLOGICAL FUNCTION - Techniques for generating microtissues, including a micro-fabricated platform including at least one micro-well including a plurality of micro-cantilevers coupled thereto and surrounded by a plurality of ridges, each micro-cantilever including a cap at a terminal end thereof. The platform can be immersed in a suspension of cells. The suspension of cells can be driven into at least one micro-well, and the ridges can be de-wetted to remove excess suspension and isolate the suspension of cells in each micro-well. The cells can be driven in the suspension of each micro-well toward a top surface of the suspension, which can be polymerized to form a matrix. The cells can be cultivated to spontaneously compact the matrix such that the micro-cantilevers anchor and constrain the contracting matrix to form a band of microtissue that spans across the micro-cantilevers. | 08-07-2014 |
20150087004 | Microfabricated 3D Cell Culture System - Device for 3D cell culture using an extracellular matrix including a substrate having at least one interior chamber, at least one opening providing access to the interior chamber for introduction of an extracellular matrix, and at least one channel disposed through at least a portion of the extra cellular matrix. | 03-26-2015 |
Patent application number | Description | Published |
20120064388 | Metal-Free Aqueous Electrolyte Energy Storage Device - An electrochemical device including a housing and a stack of electrochemical cells in the housing. Each electrochemical cell includes an anode electrode, a cathode electrode, a separator located between the anode electrode and the cathode electrode and an electrolyte. The electrochemical device also includes a current collector located between adjacent electrochemical cells, an anode bus operatively connected to the anodes of the electrochemical cells in the stack and a cathode bus operatively connected to the cathodes of the electrochemical cells in the stack. The housing, the anode electrode, the cathode electrode, the separator, the anode bus and the cathode bus are non-metallic. | 03-15-2012 |
20130017417 | Aqueous Electrolyte Energy Storage Device - An electrochemical device including a housing and a stack of electrochemical cells in the housing. Each electrochemical cell includes an anode electrode, a cathode electrode, a separator located between the anode electrode and the cathode electrode and an electrolyte. The electrochemical device also includes a current collector located between adjacent electrochemical cells, an anode bus operatively connected to the anodes of the electrochemical cells in the stack and a cathode bus operatively connected to the cathodes of the electrochemical cells in the stack. The housing, the anode electrode, the cathode electrode, the separator, the anode bus and the cathode bus are non-metallic. | 01-17-2013 |
20130059185 | Large Format Electrochemical Energy Storage Device Housing and Module - An assembly includes non-load bearing housings, each housing including several cavities. Each cavity includes a stack of freely stacked electrochemical storage cells in the housings. Each electrochemical storage cell includes an anode electrode, a cathode electrode, and a separator located between the anode electrode and the cathode electrode. The assembly is configured such that pressure applied to the assembly is born by the freely stacked electrochemical storage cells. | 03-07-2013 |
20140037996 | AQUEOUS ELECTROLYTE ENERGY STORAGE DEVICE - An electrochemical device including a housing and a stack of electrochemical cells in the housing. Each electrochemical cell includes an anode electrode, a cathode electrode, a separator located between the anode electrode and the cathode electrode and an electrolyte. The electrochemical device also includes a current collector located between adjacent electrochemical cells, an anode bus operatively connected to the anodes of the electrochemical cells in the stack and a cathode bus operatively connected to the cathodes of the electrochemical cells in the stack. The housing, the anode electrode, the cathode electrode, the separator, the anode bus and the cathode bus are non-metallic. | 02-06-2014 |
20140162090 | LARGE FORMAT ELECTROCHEMICAL ENERGY STORAGE DEVICE HOUSING AND MODULE - An assembly includes non-load bearing housings, each housing including several cavities. Each cavity includes a stack of freely stacked electrochemical storage cells in the housings. Each electrochemical storage cell includes an anode electrode, a cathode electrode, and a separator located between the anode electrode and the cathode electrode. The assembly is configured such that pressure applied to the assembly is born by the freely stacked electrochemical storage cells. | 06-12-2014 |
20150147628 | AQUEOUS ELECTROLYTE ENERGY STORAGE DEVICE - An electrochemical device including a housing and a stack of electrochemical cells in the housing. Each electrochemical cell includes an anode electrode, a cathode electrode, a separator located between the anode electrode and the cathode electrode and an electrolyte. The electrochemical device also includes a current collector located between adjacent electrochemical cells, an anode bus operatively connected to the anodes of the electrochemical cells in the stack and a cathode bus operatively connected to the cathodes of the electrochemical cells in the stack. The housing, the anode electrode, the cathode electrode, the separator, the anode bus and the cathode bus are non-metallic. | 05-28-2015 |
Patent application number | Description | Published |
20090208450 | METHOD FOR ENHANCING THE EFFICACY OF ANTIGEN SPECIFIC TUMOR IMMUNOTHERAPY - The invention provides a method for the improved processing efficiency of T cell tumor antigen epitopes using bioinformatic means. The proteolytic sites in the generation of 47 experimentally identified HLA-A2.1-restricted immunodominant tumor antigen epitopes was compared to those of 52 documented HLA-A2.1-restricted immunodominant viral antigen epitopes. The amino acid frequencies in the C-terminal cleavage sites of the tumor antigen epitopes, as well as several positions within the 10 amino acid (aa) flanking regions, were significantly different from those of the viral antigen epitopes. These two groups of epitopes may be cleaved by distinct sets of proteasomes and peptidases or similar enzymes with lower efficiencies for tumor epitopes, targeted activation of the immunoproteasomes and peptidases can be achieved that mediate the cleavage of viral epitopes in order to more effectively generate tumor antigen epitopes thus enhancing antigen-specific tumor immunotherapy. | 08-20-2009 |
20090304736 | NOVEL TUMOR ANTIGENS ELICIT ANTI-TUMOR HUMORAL IMMUNE REACTIONS IN A SUBSET OF PATIENTS WITH POLYCYTHEMIA VERA - The invention provides novel antigens, MPD5, PV13, and PV65, which belongs to the group of cryptic antigens without conventional genomic structure and is encoded by a cryptic open reading frame located in the 3′untranslated region (3′UTR) of myotrophin mRNA. The antigens elicit IgG antibody responses in a subset of PV patients, as well as patients with chronic myelogenous leukemia and prostate cancer. The translation of MPD5, PV13 and PV65 was mediated by a novel internal ribosome entry site (IRES) upstream of the open reading frame. Eliciting anti-tumor immune response against MPD5, PV13 and/or PV65 antigen in patients with myeloproliferative diseases is a novel immunotherapy. | 12-10-2009 |
20100136036 | UNCONVENTIONAL ANTIGEN TRANSLATED BY A NOVEL INTERNAL RIBOSOME ENTRY SITE ELICITS ANTITUMOR HUMORAL IMMUNE REACTIONS - The invention provides a novel antigen, MPD6, which belongs to the group of cryptic antigens without conventional genomic structure and is encoded by a cryptic open reading frame located in the 3′ untranslated region (3′UTR) of myotrophin mRNA. MPD6 elicits IgG antibody responses in a subset of PV patients, as well as patients with chronic myelogenous leukemia and prostate cancer. The translation of MPD6 was mediated by a novel internal ribosome entry site (IRES) upstream of the MPD6 reading frame. Furthermore, the MPD6-IRES mediated translation, but not myotrophin-MPD6 transcription, was significantly upregulated in response to IFN-α stimulation. These findings demonstrate that a novel IRES-mediated mechanism is responsible for the translation of unconventional self-antigen MPD6 in responsive to IFN-α stimulation. The eliciting anti-tumor immune response against unconventional antigen MPD6 in patients with myeloproliferative diseases indicates MPD6 as a target of novel immunotherapy. | 06-03-2010 |
Patent application number | Description | Published |
20090004609 | Lithography process - A lithography process for manufacturing bit-island storage mediums that results in improved resolution and uniformity between bit-islands. The lithography process includes applying a resist coating polymer to a surface of a substrate. Selected areas of the resist coating polymer are then exposed to an energy source, wherein each selected area is exposed to the energy source multiple times to provide a time-averaged exposure of the selected areas that reduces errors caused by noise associated with the energy source. After exposure of the resist coating to the energy source, a selective developer solution is applied to the resist coating to develop the fully exposed regions of the resist coating while leaving undeveloped the partially exposed regions of the resist coating. A polymer reflow material is applied to the developed resist pattern and heated to a selected temperature. The polymer reflow material and selected temperature induce reflow of the developed resist coating such that such that a circumferential diameter associated with the holes formed in the resist pattern is reduced to a desired value distance. The process of inducing reflow of the resist coating can be repeated as desired to achieve a resist pattern wherein the holes formed in the resist pattern are reduced to a desired size. The resist pattern formed on the substrate is then transferred to a magnetic medium to form the desired pattern of bit-islands. | 01-01-2009 |
20090279206 | FABRICATION OF TRAPEZOIDAL POLE FOR MAGNETIC RECORDING - A method for forming a magnetic write pole with a trapezoidal cross-section is described. The method consists of first forming a magnetic seedlayer on a base followed by depositing a removable material layer on the seedlayer, and then a resist layer on the removable material layer. A trench is then formed in the resist, and the resist is heated to cause the cross-sectional profile of the trench to assume a trapezoidal shape. The resist is then capped with another resist layer and further heated to cause the width of the trapezoidal trench to become narrower. The cap layer and removable material layer at the bottom of the trench are then removed and the trench filled with magnetic material by electroplating. The resist and seedlayer external to the trench are finally removed to form a write pole with a trapezoidal cross-section. | 11-12-2009 |
20090305173 | FORMATION OF A DEVICE USING BLOCK COPOLYMER LITHOGRAPHY - The formation of a device using block copolymer lithography is provided. The formation of the device includes forming a block copolymer structure. The block copolymer structure includes a first polymer and a second polymer. The block copolymer structure also includes a first component deposited between adjacent blocks of the first polymer and a second component deposited between adjacent blocks of the second polymer. A template is developed by removing either the first and second polymers or the first and second components from the block copolymer structure. The formation of the device also includes lithographically patterning the device utilizing the block copolymer structure template. The device may be a data storage medium. | 12-10-2009 |
20100051904 | Dual-Level Self-Assembled Patterning Method and Apparatus Fabricated Using the Method - A method of fabricating a device includes: providing a substrate having a patterned surface, depositing a first-level self-assembled material on at least a portion of the patterned surface, wherein the position and/or orientation of the first-level self-assembled material is directed by the patterned surface, to form a first nanostructure pattern, and depositing a second-level self-assembled material on at least a portion of the first nanostructure pattern to form an array of nanostructures of the second-level self-assembled material. An apparatus fabricated using the method is also provided. | 03-04-2010 |
20100104768 | METHOD OF MAKING OPTICAL TRANSDUCERS - A process for making an optical transducer that includes depositing a lower molecular weight first layer and a higher molecular weight second layer. E-beam radiation is applied to the first and second layers which are developed to form an aperture. The aperture includes a resist protrusion in the second layer. The resist protrusion protrudes outward beyond the first layer. Metal is evaporated through the aperture to form the optical transducer. The resist protrusion defines a shape of a concave metal transducer corner. | 04-29-2010 |
20100124638 | Chemical Pinning to Direct Addressable Array Using Self-Assembling Materials - A method includes: providing a substrate having a plurality of chemically contrasted alignment features, and depositing a self-assembled material on at least a portion of the substrate, wherein the position and/or orientation of substantially spherical or cylindrical domains of the self-assembled material is directed by the alignment features, to form a nanostructure pattern, and wherein the period of the alignment features is between about 2 times and about 10 times the period of the spherical or cylindrical domains. An apparatus fabricated according to the method is also provided. | 05-20-2010 |
20130010387 | POLE FOR MAGNETIC RECORDING - A method for forming a magnetic write pole with a trapezoidal cross-section is described. The method consists of first forming a magnetic seedlayer on a base followed by depositing a removable material layer on the seedlayer, and then a resist layer on the removable material layer. A trench is then formed in the resist, and the resist is heated to cause the cross-sectional profile of the trench to assume a trapezoidal shape. The resist is then capped with another resist layer and further heated to cause the width of the trapezoidal trench to become narrower. The cap layer and removable material layer at the bottom of the trench are then removed and the trench filled with magnetic material by electroplating. The resist and seedlayer external to the trench are finally removed to form a write pole with a trapezoidal cross-section. | 01-10-2013 |
Patent application number | Description | Published |
20110291655 | FAILSAFE PROTECTION FROM INDUCED RF CURRENT FOR MRI RF COIL ASSEMBLY HAVING TRANSMIT FUNCTIONALITY - An electrically-controlled failsafe switch is included in an MRI transmit-and-receive RF coil assembly so as to protect it from induced RF currents in the event it is disconnected from an MRI system, but inadvertently left linked to strong MRI RF fields during imaging procedures using other RF coils. | 12-01-2011 |
20120306499 | FAILSAFE PROTECTION FROM INDUCED RF CURRENT FOR MRI RF COIL ASSEMBLY HAVING TRANSMIT FUNCTIONALITY - An electrically-controlled failsafe switch is included in an MRI transmit-and-receive RF coil assembly so as to protect it from induced RF currents in the event it is disconnected from an MRI system, but inadvertently left linked to strong MRI RF fields during imaging procedures using other RF coils. | 12-06-2012 |
20140128723 | Reconfigurable MRI-Guided Surgical Apparatus - Apparatus associated with improved magnetic resonance imaging (MRI) guided needle biopsy procedures (e.g., breast needle biopsy) are described. One example apparatus includes a support structure configured to support a patient in a face-down prone position where a breast of the patient is positioned in a first free hanging pre-imaging position. The example apparatus includes an immobilization structure configured to reposition the breast into an immobilized position suitable for MRI and for medical instrument access. The immobilization structure may include a biopsy plate, a pressure plate, and MRI coils. The MRI coils are configured to be repositioned from a first position associated with the free hanging pre-imaging position to a second position associated with the immobilized position to facilitate improving the signal to noise ratio associated with signal received from the breast through the MRI coils. The biopsy plate is removable without removing either of the MRI coils. | 05-08-2014 |
20150323620 | Coaxial Cable Magnetic Resonance Image (MRI) Coil - Example magnetic resonance imaging (MRI) radio frequency (RF) coils are described. An MRI RF coil may include a first terminal and a second terminal that are connected by a coaxial cable. Rather than rely exclusively on two terminal passive components (e.g., resistor, inductor, capacitor), example coax MRI RF coils rely on the capacitance that can be created in the coax cable between the inner conductor and the outer conductor. The capacitance of the coil may be controlled by selectively disrupting (e.g., cutting, stripping) the outer conductor, the inner conductor, or the dielectric material disposed between the inner and outer conductor. | 11-12-2015 |
20160033594 | Magnetic Resonance Imaging (MRI) Coil With Integrated Decoupling - Example magnetic resonance imaging (MRI) radio frequency (RF) coils are described. An MRI RF coil may include an LC circuit and an integrated decoupling circuit. The integrated decoupling circuit may include a wire or other conductor that is connected to the LC circuit and that is positioned within a defined distance of the LC circuit. The integrated decoupling circuit may include a PIN diode and a tunable element. The tunable element may be tunable with respect to resistance, capacitance, or inductance, and thus may control, at least in part, the frequency at which the LC circuit resonates during RF transmission. The example MRI RF coil has more than one point of high impedance, which facilitates reducing heating and operational issues associated with conventional coils. | 02-04-2016 |
20160033598 | FAILSAFE PROTECTION FROM INDUCED RF CURRENT FOR MRI RF COIL ASSEMBLY HAVING TRANSMIT FUNCTIONALITY - An electrically-controlled failsafe switch is included in an MRI transmit-and-receive RF coil assembly so as to protect it from induced RF currents in the event it is disconnected from an MRI system, but inadvertently left linked to strong MRI RF fields during imaging procedures using other RF coils. | 02-04-2016 |
Patent application number | Description | Published |
20100216841 | 4-Fluoro-Piperidine T-Type Calcium Channel Antagonists - The present invention is directed to 4-fluoro-piperidine compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved. | 08-26-2010 |
20130018048 | OXAZOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH - The present invention is directed to certain Oxazole derivatives which are useful as modulators of Fatty Acid Amide Hydrolase (FAAH) and as FAAH imaging agents. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer Disease, and Parkinson's Disease. | 01-17-2013 |
Patent application number | Description | Published |
20090275550 | Pyridyl Amide T-Type Calcium Channel Antagonists - The present invention is directed to pyridyl amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved. | 11-05-2009 |
20100210671 | Quinazolinone T-Type Calcium Channel Antagonists - The present invention is directed to quinazolinone compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved. | 08-19-2010 |
20100216816 | PYRAZINYL AMIDE-T TYPE CALCIUM CHANNEL ANTAGONISTS - The present invention is directed to pyrazinyl amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved. | 08-26-2010 |
20100222387 | 3-Fluoro-Piperidine T-Type Calcium Channel Antagonists - The present invention is directed to 3-fluoro-piperidine compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved. | 09-02-2010 |
20100249176 | HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS - The present invention is directed to heterocycle amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved. | 09-30-2010 |
20100261724 | HETEROCYCLE PHENYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS - The present invention is directed to heterocycle phenyl amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved. | 10-14-2010 |
20110112064 | Pyridyl Amide T-Type Calcium Channel Antagonists - The present invention is directed to pyridyl amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved. | 05-12-2011 |
20120202852 | HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS - The present invention is directed to heterocycle amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved. | 08-09-2012 |
20130012526 | OXAZOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH - The present invention is directed to certain Oxazole derivatives which are useful as modulators of Fatty Acid Amide Hydrolase (FAAH) and as FAAH imaging agents. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer Disease, and Parkinson's Disease. | 01-10-2013 |
20140200222 | N-LINKED QUINOLINEAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS - The present invention is directed to N-linked quinoline amide compounds of general formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor. | 07-17-2014 |
20150065498 | N-LINKED LACTAM M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS - The present invention is directed to N-linked lactam compounds of general formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor. | 03-05-2015 |